Clinical trials: Breast Cancer Risk
Breast Cancer
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00824538
- Testing
- sunitinib malate, flow cytometry, immunohistochemistry staining method
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco
Benign Breast Disease, Fibrocystic Disease of Breast
Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer
The purpose of the study is to determine the efficacy and relapse rate of low dose, short duration treatment with tamoxifen in benign breast disease amenable to hormonal therapy with respect to etiology and estrogen receptor…
- Conditions
- Benign Breast Disease, Fibrocystic Disease of Breast, Fibroadenoma, Mastalgia
- Trial name
- NCT00999921
- Testing
- Tamoxifen, Evening Primrose Oil
- Where
- India
- Volunteers
- 256 people
- Sponsor
- Medical College and Hospital Kolkata
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
This phase II trial studies how well docetaxel or paclitaxel work in reducing chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04001829
- Testing
- Docetaxel, Paclitaxel, Quality-of-Life Assessment
- Where
- 482 sites in United States
- Volunteers
- 249 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070564
- Testing
- pegfilgrastim, AC regimen, cyclophosphamide
- Where
- 542 sites in United States, Canada and 1 more
- Volunteers
- 3,294 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard…
- Trial name
- NCT00544167
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 45 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
We aim to compare the sensitivity of mammography to the sensitivity of Molecular Breast Imaging (a new gamma-camera based breast imaging technology) in women with dense breast tissue who are at increased risk for breast cancer.
- Trial name
- NCT00620373
- Testing
- Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
- Where
- United States
- Volunteers
- 969 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Stage IV Breast Cancer
Vaccination of High Risk Breast Cancer Patients
Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.
- Trial name
- NCT01390064
- Testing
- Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Breast Cancer
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the…
- Trial name
- NCT02142959
- Testing
- Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion
- Where
- 27 sites in United States
- Volunteers
- 187 people
- Sponsor
- Biogen
Breast Cancer
Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation
The purpose of this study is to learn whether daily use of Duavee® is accepted and tolerated by peri- and post-menopausal women at moderate risk for development of breast cancer.
- Trial name
- NCT02729701
- Testing
- Duavee
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Kansas Medical Center
HER2/Neu Positive, Progesterone Receptor Positive
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01275677
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 1,283 sites in United States, Canada and 2 more
- Volunteers
- 3,270 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Soy Protein and Breast Cancer Risk Reduction
Soy consumption has been associated with reduced risk for developing breast cancer. Ovarian hormones and breast density are considered breast cancer risk markers.
- Trial name
- NCT00204477
- Testing
- soy milk, cow's milk
- Where
- United States
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
DCIS, Ductal Carcinoma in Situ
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS.
- Trial name
- COMET (NCT02926911)
- Testing
- Surgery, Active Monitoring
- Where
- 141 sites in United States
- Volunteers
- 997 people
- Sponsor
- Alliance Foundation Trials, LLC.
Invasive Breast Cancer
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone…
- Trial name
- CemiHALT (NCT04243616)
- Testing
- Cemiplimab, Paclitaxel, Carboplatin (not mandatory)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer
Olive Oil for High Risk Breast Cancer Prevention in Women
This is a pilot study evaluating the effect of hydroxytyrosol, a component of olive oil, on mammographic density in women at high risk of developing breast cancer.
- Trial name
- NCT02068092
- Testing
- Hydroxytyrosol
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer
Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer
RATIONALE: Screening tests may help doctors find cancer cells early and plan better treatment for breast cancer. It is not yet known whether positron emission mammography is more effective than standard mammography in finding…
- Trial name
- NCT00896649
- Testing
- questionnaire administration, digital mammography, positron emission mammography
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Breast Cancer Stage II
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage…
- Trial name
- ACNTBC (NCT05558722)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Breast Cancer
Protocol for Women at Increased Risk of Developing Breast Cancer
To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.
- Trial name
- NCT00291694
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Breast Carcinoma
Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
This trial studies how well a lifestyle intervention works in reducing breast cancer risk through changing body composition and decreasing inflammation in normal weight women.
- Trial name
- NCT04267796
- Testing
- Aerobic Exercise, Dietary Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Dietary Fat, Eicosanoids and Breast Cancer Risk
The primary objective of this investigation is to determine whether diets designed to increase plasma n3 concentrations (a low fat diet, with or without n3 fatty acid enrichment), will favorably affect sex hormone distribution in…
- Trial name
- NCT01824498
- Testing
- Low Fat diet, Low Fat high n3 diet, High Fat Diet
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- USDA Grand Forks Human Nutrition Research Center
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer…
- Trial name
- OASIS-4 (NCT05587296)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 102 sites in Austria, Belgium and 14 more
- Volunteers
- 474 people
- Sponsor
- Bayer